Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae

European Cells and Materials

Volumn 28, Issue , 2014, Pages 152-165

  Krause, M ^a,b   Soltau, M ^a   Zimmermann, E A ^a   Hahn, M ^a   Kornet, J ^a,c   Hapfelmeier, A ^d   Breer, S ^a   Morlock, M ^c   Wulff, B ^a   Puschel K ^a   Glueer, C C ^e   Amling, M ^a   Busse, B ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c HAMBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Alendronate; Histomorphometry; Microcomputed tomography; Microdamage; Mineralisation; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BIOMECHANICS; BODY MASS; BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUMBAR VERTEBRA; MORPHOMETRICS; OSTEOLYSIS; OSTEOPOROSIS; TRABECULAR BONE; VERY ELDERLY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BIOMECHANICAL PHENOMENA; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; FEMALE; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84907843038     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v028a12     Document Type: Article

References (77)

1. Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22: 1759-1765.
2. Allen MR, Burr DB (2011) Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone 49: 56-65.
3. Allen MR, Iwata K, Sato M, Burr DB (2006) Raloxifene enhances vertebral mechanical properties independent of bone density. Bone, 39:1130-1135.
4. Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD (2008) Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis Int 19: 329-337.
5. Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporosis Int 14 Suppl 3: S13-18.
6. Aruwajoye OO, Patel MK, Allen MR, Burr DB, Aswath PB, Kim HK (2013) Microcrack density and nanomechanical properties in the subchondral region of the immature piglet femoral head following ischemic osteonecrosis. Bone 52: 632-639.
7. Bala Y, Farlay D, Chapurlat RD, Boivin G (2011) Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol 165: 647-655.
8. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2586.
9. Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC, Genant HK, Cummings SR (2001) Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 16: 1108-1119.
10. Beck TJ, Petit MA, Wu G, LeBoff MS, Cauley JA, Chen Z (2009) Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women’s health initiative-observational study. J Bone Miner Res 24: 1369-1379.
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535-1541.
12. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR FLEX Research Group; (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
13. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27: 243-254.
14. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687-694.
15. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA Alendronate Phase III Osteoporosis Treatment Study Group; (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.
16. Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate- treated postmenopausal women. Osteoporosis Int 20: 793-800.
17. Bottai V, Giannotti S, Dell’osso G, De Paola G, Menconi A, Falossi F, Raffaetà G, Guido G (2014) Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases. Osteoporosis Int 25: 993-997.
18. Breer S, Krause M, Busse B, Hahn M, Rüther W, Morlock MM, Amling M, Zustin J (2012) Analysis of retrieved hip resurfacing arthroplasties reveals the interrelationship between interface hyperosteoidosis and demineralization of viable bone trabeculae. J Orthop Res 30: 1155-1161.
19. Burghardt AJ, Kazakia GJ, Laib A, Majumdar S (2008) Quantitative assessment of bone tissue mineralization with polychromatic micro-computed tomography. Calcif Tissue Int 83: 129-138.
20. Burr DB, Stafford T (1990) Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage. Clin Orthop Rel Res 260: 305-308.
21. Busse B, Hahn M, Soltau M, Zustin J, Püschel K, Duda GN, Amling M (2009) Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. Bone 45: 1034-1043.
22. Carretta R, Luisier B, Bernoulli D, Stussi E, Muller R, Lorenzetti S (2013) Novel method to analyze post-yield mechanical properties at trabecular bone tissue level. J Mech Behav Biomed Mater 20: 6-18.
23. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22: 1502-1509.
24. Chng HK, Ramli HN, Yap AU, Lim CT (2005) Effect of hydrogen peroxide on intertubular dentine. J Dent 33: 363-369.
25. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082.
26. Day JS, Ding M, Bednarz P, van der Linden JC, Mashiba T, Hirano T, Johnston CC, Burr DB, Hvid I, Sumner DR, Weinans H (2004) Bisphosphonate treatment affects trabecular bone apparent modulus through microarchitecture rather than matrix properties. J Orthop Res 22: 465-471.
27. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28: 2-17.
28. DePaula CA, Truncale KG, Gertzman AA, Sunwoo MH, Dunn MG (2005) Effects of hydrogen peroxide cleaning procedures on bone graft osteoinductivity and mechanical properties. Cell Tissue Bank 6: 287-298.
29. Ding M, Day JS, Burr DB, Mashiba T, Hirano T, Weinans H, Sumner DR, Hvid I (2003) Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcified tissue international, 72:737-744.
30. Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL (2012) Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 27: 672-678.
31. Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 1 Suppl 6: S55-S65.
32. Glüer C-C, Krause M, Museyko O, Wulff B, Campbell G, Damm T, Daugschies M, Huber G, Lu Y, Peña J, Waldhausen S, Bastgen J, Rohde K, Breer S, Steinebach I, Thomsen F, Amling M, Barkmann R, Engelke K, Morlock M, Pfeilschifter J, Püschel K (2013) New horizons for the in vivo assessment of major aspects of bone quality. Microstructure and material properties assessed by quantitative computed tomography and quantitative ultrasound methods developed by the BioAsset consortium. Osteology 22: 223-233.
33. Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL (2010) Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46: 666-672.
34. Guerri-Fernandez RC, Nogues X, Torres Del Pliego E, Puig L, García-Giralt N, Yoskovitz G, Mellibovsky L, Hansma PK, Díez-Pérez A (2013) Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 28: 162-168.
35. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344-1352.
36. Hernandez CJ (2008) How can bone turnover modify bone strength independent of bone mass? Bone 42: 1014-1020.
37. Joiner A (2007) Review of the effects of peroxide on enamel and dentine properties. J Dent 35: 889-896.
38. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22: 149-157.
39. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512-520.
40. Krause M, Breer S, Hahn M, Rüther W, Morlock MM, Amling M, Zustin J (2012a) Cementation and interface analysis of early failure cases after hip-resurfacing arthroplasty. Int Orthop 36: 1333-1340.
41. Krause M, Breer S, Mohrmann B, Vettorazzi E, Marshall RP, Amling M, Barvencik F (2012b) Influence of non-traumatic thoracic and lumbar vertebral fractures on sagittal spine alignment assessed by radiation-free spinometry. Osteoporosis Int 24: 1859-1868.
42. Krause M, Museyko O, Breer S, Wulff B, Duckstein C, Vettorazzi E, Glueer C, Püschel K, Engelke K, Amling M (2014) Accuracy of trabecular structure by HR-pQCT compared to gold standard muCT in the radius and tibia of patients with osteoporosis and long-term bisphosphonate therapy. Osteoporosis Int 25 :1595-1606.
43. Launey ME, Ritchie RO (2009) On the fracture toughness of advanced materials. Adv Mater 21: 2103-2110.
44. Lee TC, Arthur TL, Gibson LJ, Hayes WC (2000) Sequential labelling of microdamage in bone using chelating agents. J Orthopaed Res 18: 322-325.
45. Lee TC, Mohsin S, Taylor D, Parkesh R, Gunnlaugsson T, O’Brien FJ, Giehl M, Gowin W (2003) Detecting microdamage in bone. J Anat 203: 161-172.
46. Li D, Bi L, Meng G, Wang J, Lv R, Liu M, Liu J, Hu Y (2011) Mineral status and mechanical properties of cancellous bone exposed to hydrogen peroxide for various time periods. Cell Tissue Bank 12: 51-58.
47. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613-620.
48. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524-531.
49. Mulder L, Koolstra JH, Van Eijden TM (2004) Accuracy of microCT in the quantitative determination of the degree and distribution of mineralization in developing bone. Acta Radiol 45: 769-777.
50. Museyko O, Heinemann A, Krause M, Wulff B, Amling M, Püschel K, Glüer CC, Kalender W, Engelke K (2014) A low-radiation exposure protocol for 3D QCT of the spine. Osteoporosis Int 25: 983-992.
51. Nyman JS, Yeh OC, Hazelwood SJ, Martin RB (2004) A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage. Bone 35: 296-305.
52. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15: 1384-1392.
53. Ridha H, Thurner PJ (2013) Finite element prediction with experimental validation of damage distribution in single trabeculae during three-point bending tests. J Mech Behav Biomed Mater 27: 94-106.
54. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185-191.
55. Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K (2010) Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). J Bone Miner Res 25: 48-55.
56. Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporosis Int 17: 986-995.
57. Shane E, Burr D, Ebeling PR, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267-2294.
58. Slyfield CR, Tkachenko EV, Fischer SE, Ehlert KM, Yi IH, Jekir MG, O’Brien RG, Keaveny TM, Hernandez CJ (2012) Mechanical failure begins preferentially near resorption cavities in human vertebral cancellous bone under compression. Bone 50: 1281-1287.
59. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H (2007) Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41: 378-385.
60. Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP (2011) Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 49: 1279-1289.
61. Vaishya R, Vaish A, Nadeem A (2013) Bisphosphonate-induced atypical subtrochanteric femoral fracture. BMJ Case Rep pii: bcr2013201931.
62. Wang X, Allen MR, Burr DB, Lavernia EJ, Jeremic B, Fyhrie DP (2008) Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone. Bone 43: 775-780.
63. Wasserman N, Yerramshetty J, Akkus O (2005) Microcracks colocalize within highly mineralized regions of cortical bone tissue. Eur J Morphol 42: 43-51.
64. Zanchetta MB, Diehl M, Buttazzoni M, Galich A, Silveira, Bogado CE, Zanchetta JR (2014) Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur. J Bone Miner Res 29: 999-1004.
65. Zimmermann EA, Schaible E, Bale H, Barth HD, Tang SY, Reichert P, Busse B, Alliston T, Ager JW3rd, Ritchie RO (2011) Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales. Proc Natl Acad Sci USA 108: 14416-14421.
66. Allen MR, Kubek DJ, Burr DB (2010) Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 25: 98-105.
67. Deuerling JM, Rudy DJ, Niebur GL, Roeder RK (2010) Improved accuracy of cortical bone mineralization measured by polychromatic microcomputed tomography using a novel high mineral density composite calibration phantom. Med Phys 37: 5138-5145.
68. Hu JH, Ding M, Søballe K, Bechtold JE, Danielsen CC, Day JS, Hvid I (2002) Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone 31: 591-597.
69. Lin JH (1996) Bisphosphonates: A review of their pharmacokinetic properties. Bone 18: 75-85.
70. Nazarian A, Snyder BD, Zurakowski D, Müller R (2008) Quantitative micro-computed tomography: A non-invasive method to assess equivalent bone mineral density. Bone 43: 302-311.
71. Penel G, Delfosse C, Descamps M, Leroy G (2005) Composition of bone and apatitic biomaterials as revealed by intravital Raman microspectroscopy. Bone 36: 893-901.
72. Petra M, Anastassopoulou J, Theologis T, Theophanides T (2005) Synchrotron micro-FT-IR spectroscopic evaluation of normal paediatric human bone. J Mol Struct 733: 101-110.
73. Rodan GA (1998) Mechanisms of action of bisphosphonates. Ann Rev Pharmacol Toxicol 38: 375-388.
74. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl): 2961-2978.
75. Shahnazari M, Yao W, Dai W, Wang B, Ionova-Martin SS, Ritchie RO, Heeren D, Burghardt AJ, Nicolella DP, Kimiecik MG, Lane NE (2010) Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 46: 1267-1274.
76. Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32: 45-55.
77. Wagner DW, Lindsey DP, Beaupre GS (2011) Deriving tissue density and elastic modulus from microCT bone scans. Bone 49: 931-938.